the 16th, NKCL Bio Group signed a MOA with Hanyang Institute for Precision
Therapeutics(HY-IPT) at ‘Hanyang University ERICA Campus’.
the era of the 4th industrial revolution, Hanyang University's personalized
medicine research institute has established a bio convergence core research
group and core infrastructure that can lead the life science basics and
convergence fields. It is predicted that full-cycle research will be conducted
on smart disease diagnosis and treatment convergence technology from molecular
level to clinical, such as drug delivery, bio big data, and bio artificial
this business agreement, it is more meaningful that not only the academic community
but also related companies will be able to grow together through industry,
academia, research, hospital, and government partnerships in the new industry
of personalized medicine and life science.
University's personalized medicine research center is operated with four
research centers: customized drug development for cancer and geriatric
diseases, customized immune drug development, and bio-big data artificial
intelligence drug development.
Bio Group is the first company to sign a MOA with Hanyang Institute for
to the spread of the Omicron virus, the signing ceremony was held with a
minimum number of participants, including Dong-hwa Shin, hte Chairman of NKCL
Bio Group and Hye-myung Seo, Research Director
of Hanyang University ERICA.
addition to NKCL Bio Group, Hanyang Institute for Precision
Therapeutics(HY-IPT) will cooperate with domestic pharmaceutical and
biopharmaceutical companies such as Dong-A Pharm, Kwangdong Pharm, Samjin
Pharm, Kolon Pharm, LG Chem, Aju Pharm, and Huons.
this agreement, the two companies will lead cooperation in research and
development projects, mutual information exchange, human resource development
through development of subjects and educational programs and plan to strengthen
official from the company said, “By establishing a partnership in the new
industry of personalized medicine, we have been able to achieve the purpose of
eradicating diseases and promoting health. We hope that joint research in areas
such as personalized medicine and development of educational programs, to be
actively carried out.”
addition, he added, “Through the active mutual exchange of this educational
development program and human resources nurturing project, we will discover
immune experts with expertise, and we hope that it will serve as an opportunity
for win-win development between the two institutions at a time when the
interest and importance of immunity has increased due to COVID-19.”